Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

chloroquine (Rx)Brand and Other Names:Aralen, Chloroquine phosphate

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 250mg
  • 500mg
more...

Malaria

Prevention: 500 mg (300 mg base) PO once/week

Non-chloroquine-resistant

  • 1 g (600 mg base) PO, THEN
  • 500 mg (300 mg base) PO 6-8 hours later, THEN
  • 500 mg (300 mg base) PO at 24 hours & 48 hours after initial dose

Amebiasis, Extraintestinal

1 g (600 mg base) PO qDay for 2 days, THEN

500 mg (300 mg base) qDay for 14-21 days

Porphyria Cutanea Tarda (Off-label)

125-250 mg (75-150 mg base) PO twice weekly

Glioblastoma (Orphan)

Orphan designation for treatment of glioblastoma multiforme

Sponsor

  • DualTpharma B.V.; Boschstraat 111-D01; 6211 A W Maastricht; Netherlands

Dosage Forms & Strengths

tablet

  • 250mg
  • 500mg
more...

Malaria

Prophylaxis: 5 mg/kg PO q1Week 

Treatment

  • 1st dose: 10 mg/kg PO x1 dose
  • 6 hours after 1st dose: 5 mg/kg PO qDay x2 days

Porphyria Cutanea Tarda (Off-label)

Dosing schedules not well established in children

Case reports describe dosage regimens that are effective yet tolerated, such as 12.5 mg PO twice weekly over 2 yr in a child aged 4-6 yr, and 100 mg PO twice weekly over 5 months in a child aged 12 yr; mg/kg dosing not reported

Next

Interactions

Interaction Checker

chloroquine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Abnormal ECG

            Prolonged QT interval

            Amnesia

            Pruritus

            Diarrhea,

            Loss of appetite

            Nausea

            Stomach cramps

            Vomiting

            Methemoglobinemia (rare)

            Muscle weakness

            Retinopathy

            Previous
            Next

            Warnings

            Black Box Warnings

            Physicians should completely familiarize themselves with the complete contents of the package insert before prescribing chloroquine phosphate

            Contraindications

            Hypersensitivity to chloroquine, 4-aminoquinolones

            Psoriasis, porphyria, retinal or visual field changes

            Cautions

            For prevention, may use proguanil concomitantly

            Chloroquine not effective in most areas; CDC recommends mefloquine or atovaquone/proguanil - check CDC traveler information for specific recommendations for region

            Caution with G-6-PD deficiency

            Monitor CBC periodically with prolonged therapy

            Caution with history of auditory damage

            Caution with hepatic disease, alcoholism, and coadministration with other hepatotoxic drugs

            May provoke seizures in patients with history of epilepsy

            Antacids and kaolin reduce chloroquine absorption; separate administration by at least 4 hr

            Retinopathy/maculopathy, as well as macular degeneration reported; irreversible retinal damage has been observed in patients who have received long-term or high-dosage 4-aminoquinoline therapy

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: not available

            Lactation: enters breast milk/not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Active against erythrocytic forms of Plasmodium vivax & P. malariae and most strains of Plasmodium falciparum

            Precise mechanism not known

            Absorption

            Bioavailability: ~89%

            Peak plasma time: 1-2 hr

            Distribution

            Distributed widely in body tissues (eg, eyes, heart, kidneys, liver, lungs) where retention prolonged; crosses placenta; enters breast milk

            Metabolism

            Partially in liver

            Elimination

            Half-life: 3-5 days

            Excretion: urine (~70% as unchanged drug); acidification of urine increases elimination

            Small amounts may be present in urine months following discontinuation of therapy

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.